Morgan Stanley analyst Vikram Purohit assumed coverage of Halozyme Therapeutics with an Overweight rating and price target of $65, up from $53. The company offers "defensive properties" and pipeline optionality, Purohit tells investors in a research note. The analyst believes updates from the pipeline and Wave 3 products should keep driving interest in the shares in 2023. Halozyme has a "diversified revenue streams through its Enhanze platform," writes Purohit.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme price target raised to $68 from $55 at Benchmark
- Halozyme initiated with an Overweight at Wells Fargo
- Halozyme reaffirms FY22 non-GAAP EPS view $2.10-$2.25, consensus $2.04
- HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
- Halozyme reports Q3 non-GAAP EPS 74c, consensus 51c